157 related articles for article (PubMed ID: 30987032)
1. CDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells.
Ahmed RL; Shaughnessy DP; Knutson TP; Vogel RI; Ahmed K; Kren BT; Trembley JH
Pharmaceuticals (Basel); 2019 Apr; 12(2):. PubMed ID: 30987032
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
3. CDK11 requires a critical activator SAP30BP to regulate pre-mRNA splicing.
Wang C; Xu L; Du C; Yun H; Wang K; Liu H; Ye M; Fan J; Zhou Y; Cheng H
EMBO J; 2023 Dec; 42(24):e114051. PubMed ID: 38059508
[TBL] [Abstract][Full Text] [Related]
4. Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection.
Loyer P; Trembley JH; Grenet JA; Busson A; Corlu A; Zhao W; Kocak M; Kidd VJ; Lahti JM
J Biol Chem; 2008 Mar; 283(12):7721-32. PubMed ID: 18216018
[TBL] [Abstract][Full Text] [Related]
5. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.
Bhatt KV; Spofford LS; Aram G; McMullen M; Pumiglia K; Aplin AE
Oncogene; 2005 May; 24(21):3459-71. PubMed ID: 15735667
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth.
Zhou Y; Han C; Li D; Yu Z; Li F; Li F; An Q; Bai H; Zhang X; Duan Z; Kan Q
Sci Rep; 2015 May; 5():10433. PubMed ID: 25990212
[TBL] [Abstract][Full Text] [Related]
7. The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer.
Zhou Y; Shen JK; Hornicek FJ; Kan Q; Duan Z
Oncotarget; 2016 Jun; 7(26):40846-40859. PubMed ID: 27049727
[TBL] [Abstract][Full Text] [Related]
8. Failure to proliferate and mitotic arrest of CDK11(p110/p58)-null mutant mice at the blastocyst stage of embryonic cell development.
Li T; Inoue A; Lahti JM; Kidd VJ
Mol Cell Biol; 2004 Apr; 24(8):3188-97. PubMed ID: 15060143
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Structure-Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold.
Li Z; Ishida R; Liu Y; Wang J; Li Y; Gao Y; Jiang J; Che J; Sheltzer JM; Robers MB; Zhang T; Westover KD; Nabet B; Gray NS
Eur J Med Chem; 2022 Aug; 238():114433. PubMed ID: 35597007
[TBL] [Abstract][Full Text] [Related]
10. Mislocalization of CDK11/PITSLRE, a regulator of the G2/M phase of the cell cycle, in Alzheimer disease.
Bajić VP; Su B; Lee HG; Kudo W; Siedlak SL; Zivković L; Spremo-Potparević B; Djelic N; Milicevic Z; Singh AK; Fahmy LM; Wang X; Smith MA; Zhu X
Cell Mol Biol Lett; 2011 Sep; 16(3):359-72. PubMed ID: 21461981
[TBL] [Abstract][Full Text] [Related]
11. The cyclin-dependent kinase 11 interacts with NOT2.
Shi J; Nelson MA
Biochem Biophys Res Commun; 2005 Sep; 334(4):1310-6. PubMed ID: 16039607
[TBL] [Abstract][Full Text] [Related]
12. Critical role of CDK11(p58) in human breast cancer growth and angiogenesis.
Chi Y; Huang S; Peng H; Liu M; Zhao J; Shao Z; Wu J
BMC Cancer; 2015 Oct; 15():701. PubMed ID: 26470709
[TBL] [Abstract][Full Text] [Related]
13. The Emerging Picture of CDK11: Genetic, Functional and Medicinal Aspects.
Dos Santos Paparidis NF; Canduri F
Curr Med Chem; 2018; 25(8):880-888. PubMed ID: 28814241
[TBL] [Abstract][Full Text] [Related]
14. The cyclin-dependent kinase 11 interacts with 14-3-3 proteins.
Feng Y; Qi W; Martinez J; Nelson MA
Biochem Biophys Res Commun; 2005 Jun; 331(4):1503-9. PubMed ID: 15883043
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the CDK11 kinase domain bound to the small-molecule inhibitor OTS964.
Kelso S; O'Brien S; Kurinov I; Angers S; Sicheri F
Structure; 2022 Dec; 30(12):1615-1625.e4. PubMed ID: 36327972
[TBL] [Abstract][Full Text] [Related]
16. [Biological role and prognostic significance of genetic alterations in human malignant melanomas].
Vízkeleti L
Magy Onkol; 2015 Sep; 59(3):268-72. PubMed ID: 26339916
[TBL] [Abstract][Full Text] [Related]
17. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
18. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of beta1,4-galactosyltransferase 1 inhibits CDK11(p58)-mediated apoptosis induced by cycloheximide.
Li Z; Wang H; Zong H; Sun Q; Kong X; Jiang J; Gu J
Biochem Biophys Res Commun; 2005 Feb; 327(2):628-36. PubMed ID: 15629159
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of CDK11 in cancer.
Blazek D
Clin Transl Med; 2023 Mar; 13(3):e1201. PubMed ID: 36855776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
